Cargando…
How Clinical Practice Research Datalink data are used to support pharmacovigilance
Pharmacovigilance can be defined as the science of monitoring medicines and vaccines after license for use, the purpose of which is to quantify and characterise the safety profile of a medicine, identify previously unknown adverse reactions, inform risk-benefit assessment, and support the developmen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545638/ https://www.ncbi.nlm.nih.gov/pubmed/31210923 http://dx.doi.org/10.1177/2042098619854010 |
_version_ | 1783423414769287168 |
---|---|
author | Ghosh, Rebecca E. Crellin, Elizabeth Beatty, Sue Donegan, Katherine Myles, Puja Williams, Rachael |
author_facet | Ghosh, Rebecca E. Crellin, Elizabeth Beatty, Sue Donegan, Katherine Myles, Puja Williams, Rachael |
author_sort | Ghosh, Rebecca E. |
collection | PubMed |
description | Pharmacovigilance can be defined as the science of monitoring medicines and vaccines after license for use, the purpose of which is to quantify and characterise the safety profile of a medicine, identify previously unknown adverse reactions, inform risk-benefit assessment, and support the development of actions that can be taken to reduce risks, optimise benefits and monitor their effectiveness. This review discusses the Clinical Practice Research Datalink (CPRD), which is the source of the largest research database in the UK with longitudinal, representative primary care data linked to data from other healthcare settings. CPRD supports international pharmacovigilance by providing a large, anonymised representative general population database with comprehensive capture of patient risk factors and outcomes to researchers within academic, regulatory and pharmaceutical organisations. The specific advantages of CPRD data are discussed in the context of the ‘six Vs of big data’ including volume, velocity, variety, veracity, validity and value. Examples of where CPRD data have been used for pharmacovigilance research and how these have fed into guidelines and policy are discussed. |
format | Online Article Text |
id | pubmed-6545638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-65456382019-06-17 How Clinical Practice Research Datalink data are used to support pharmacovigilance Ghosh, Rebecca E. Crellin, Elizabeth Beatty, Sue Donegan, Katherine Myles, Puja Williams, Rachael Ther Adv Drug Saf Review Pharmacovigilance can be defined as the science of monitoring medicines and vaccines after license for use, the purpose of which is to quantify and characterise the safety profile of a medicine, identify previously unknown adverse reactions, inform risk-benefit assessment, and support the development of actions that can be taken to reduce risks, optimise benefits and monitor their effectiveness. This review discusses the Clinical Practice Research Datalink (CPRD), which is the source of the largest research database in the UK with longitudinal, representative primary care data linked to data from other healthcare settings. CPRD supports international pharmacovigilance by providing a large, anonymised representative general population database with comprehensive capture of patient risk factors and outcomes to researchers within academic, regulatory and pharmaceutical organisations. The specific advantages of CPRD data are discussed in the context of the ‘six Vs of big data’ including volume, velocity, variety, veracity, validity and value. Examples of where CPRD data have been used for pharmacovigilance research and how these have fed into guidelines and policy are discussed. SAGE Publications 2019-05-31 /pmc/articles/PMC6545638/ /pubmed/31210923 http://dx.doi.org/10.1177/2042098619854010 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Ghosh, Rebecca E. Crellin, Elizabeth Beatty, Sue Donegan, Katherine Myles, Puja Williams, Rachael How Clinical Practice Research Datalink data are used to support pharmacovigilance |
title | How Clinical Practice Research Datalink data are used to support pharmacovigilance |
title_full | How Clinical Practice Research Datalink data are used to support pharmacovigilance |
title_fullStr | How Clinical Practice Research Datalink data are used to support pharmacovigilance |
title_full_unstemmed | How Clinical Practice Research Datalink data are used to support pharmacovigilance |
title_short | How Clinical Practice Research Datalink data are used to support pharmacovigilance |
title_sort | how clinical practice research datalink data are used to support pharmacovigilance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545638/ https://www.ncbi.nlm.nih.gov/pubmed/31210923 http://dx.doi.org/10.1177/2042098619854010 |
work_keys_str_mv | AT ghoshrebeccae howclinicalpracticeresearchdatalinkdataareusedtosupportpharmacovigilance AT crellinelizabeth howclinicalpracticeresearchdatalinkdataareusedtosupportpharmacovigilance AT beattysue howclinicalpracticeresearchdatalinkdataareusedtosupportpharmacovigilance AT donegankatherine howclinicalpracticeresearchdatalinkdataareusedtosupportpharmacovigilance AT mylespuja howclinicalpracticeresearchdatalinkdataareusedtosupportpharmacovigilance AT williamsrachael howclinicalpracticeresearchdatalinkdataareusedtosupportpharmacovigilance |